biotech / news / / The Manila Times
Rhapsido recommended in 2026 International Urticaria Guideline for all patients who remain symptomatic after H1-antihistamine treatment.
The European Commission has approved Rhapsido (remibrutinib) as the first oral targeted CSU treatment.
KEY POINTS
- REMIX-1 and REMIX-2 studies showed Rhapsido provides significant CSU symptom improvement as early as Week 1.
- Rhapsido requires no laboratory monitoring and has no liver safety concerns in clinical trials.
- Rhapsido is newly recommended in the 2026 International Urticaria Guideline for antihistamine-refractory CSU.
COMPANIES
Summarized by Newsio from The Manila Times. How we summarize →